Dr. Nathaniel Chin discusses UW–Madison role in Alzheimer’s blood tests on regional media outlets

Nathaniel Chin, MD, medical director of the WRAP study, appeared on numerous Wisconsin news outlets to discuss the recent Food and Drug Administration (FDA) approval of a blood test for Alzheimer’s disease. The accuracy of the blood test was validated using data samples from the Wisconsin Alzheimer’s Disease Research Center (ADRC) and the Wisconsin Registry for Alzheimer’s Prevention (WRAP).

UW–Madison research helps launch first FDA-cleared blood test for Alzheimer’s disease

In a crucial advancement for Alzheimer’s disease diagnosis, the U.S. Food and Drug Administration (FDA) granted clearance for an Alzheimer’s disease blood test on May 16, 2025. The test is an in vitro diagnostic (IVD) assay capable of detecting amyloid — a key protein involved in Alzheimer’s disease — in blood. Data samples used to evaluate the validity of the test are from research conducted at the University of Wisconsin–Madison.

Dr. Sterling Johnson discusses blood testing for Alzheimer’s disease on neurology podcast

In the latest episode of the podcast Expert Voices in Dementia, Sterling Johnson, PhD, shares news about detecting Alzheimer’s disease through blood testing and the important implications this research could have on Alzheimer’s disease treatment. Johnson’s lab is investigating p-tau217 as a blood-based biomarker for early detection of Alzheimer’s disease.